Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINOAS: Aflibercept + FOLFIRI in 1st-line mCRC
NCT02624726Phase 2Unknown
- Sponsor
- Hellenic Oncology Research Group
- Start
- Jan 2016
- Primary completion
- Oct 2018
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of aflibercept in metastatic colorectal cancer (mCRC), sponsored by Hellenic Oncology Research Group. Status: unknown.
02
Drugs
aflibercept
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02624726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02624726.